Sulfonylurea derivatives glibenclamide and tolbutamide are selective blockers of ATP-sensitive K4 (KATP) channels. However, their ability to prevent cellular K4 loss and shortening of action potential duration during ischemia or hypoxia in the intact heart is modest compared with their efficacy at blocking KATP channels in excised membrane patches. In the isolated arterially perfused rabbit interventricular septum, the increase in unidirectional K4 efflux and shortening of action potential duration during substrate-free hypoxia were effectively blocked by glibenclamide, but only by very high concentrations (100 ,uM); during hypoxia with glucose present, glibenclamide was only partially effective at reducing K4 loss. During total global ischemia (10 minutes), up to 100 FM glibenclamide or 1 mM tolbutamide attenuated shortening of action potential duration but only reduced [K],, accumulation by a maximum of 32±6%. In isolated patch-clamped guinea pig ventricular myocytes in which the whole-cell ATP-sensitive K4 current was activated by exposure to the metabolic inhibitors, glibenclamide (up to 100 ,M) and tolbutamide (10 mM) were only partially effective at blocking the whole-cell ATP-sensitive K4 current (maximum block, 51±10% and 50±9%, respectively), especially when ADP was included in the patch electrode solution. In inside-out membrane patches excised from these myocytes, glibenclamide blocked unitary currents through KATP channels with a Kd of 0.5 ,uM and a Hill coefficient of 0.5 in the absence of ADP at the cytosolic membrane surface, but block was incomplete when 100 ,uM ADP (+2 mM free Mg2+) was present. ADP had a similar effect on block of KATP channels by tolbutamide. These findings suggest that free cytosolic [ADP], which rises rapidly to the 100 ,uM range during early myocardial ischemia and hypoxia, may account for the limited efficacy of sulfonylureas at blocking ischemic and hypoxic cellular K+ loss under these conditions. (Circulation Research 1991;69:623-637 
0 accumulation results primarily from an increase in K' efflux rather than decreased K' influx, suggesting that Na+-K+ pump dysfunction is not the to lactate and inorganic phosphate efflux to balance transmembrane charge movement. 9 Sulfonylurea drugs, which are selective blockers of KATP channels, have been used to estimate the contribution of KATP channels to cellular K' loss and action potential duration (APD) shortening during myocardial ischemia and hypoxia and to evaluate their potential antiarrhythmic usefulness. In high concentrations relative to those required to suppress KATP channels in excised membrane patches, the sulfonylurea glibenclamide only modestly reduced ischemic [K'] . accumulation in most,10-13 but not all,14 studies. Pretreatment with glibenclamide prevented APD shortening during hypoxia, 1315 but glibenclamide did not reverse APD short-ening if administered during hypoxia in all studies (compare References 13 and 16). Before concluding from these results that KATP channels make a limited contribution to ischemic and hypoxic K' loss, however, it must be established that sulfonylureas effectively block KATP channels under conditions likely to occur during ischemia and hypoxia in the intact heart. The purpose of this study was to further characterize the effects of sulfonylureas on cellular K' loss and APD shortening during hypoxia and ischemia in intact heart muscle, to determine whether sulfonylureas are effective at suppressing the whole-cell ATP-sensitive K' current (IKATW) activated by complete metabolic inhibition in isolated ventricular myocytes, and to identify potential factors that might interfere with the ability of sulfonylureas to block KATP channels. The findings indicate that sulfonylureas are poor blockers of KATP channels in both the intact heart and isolated myocytes when free cytosolic [ADP] exceeds 10 gM, which at least partly accounts for their limited effectiveness at reducing cellular K' loss during myocardial ischemia and hypoxia.
Materials and Methods Intact Isolated Heart Studies
Preparation and experimental setup. The experimental model was the isolated arterially perfused rabbit interventricular septum.17 Male New Zealand White rabbits (2-3 kg) were heparinized and anesthetized using an overdose of intravenously administered pentobarbital sodium. The heart was then removed through a thoracotomy incision, and a well-perfused portion of the interventricular septum was isolated and mounted in a nitrogen-filled chamber that was maintained at 37°C. The septal branch of the left coronary artery was cannulated, and the septum was perfused using a perfusion pump that maintained a flow rate of 1.75 ml* g. min-m at 37C. A polyethylene tube (PE-90) anchored at the base of the septum was used to collect venous effluent. A ligature was placed at the apex of the septum, which was tied to a tension transducer. The perfusate was a modified Tyrode's solution consisting of (mM) NaCl 120, KCl 4, CaCl2 1.5, NaHCO3 25, NaH2PO4 0.44, MgCl2 1, dextrose 5.6, and insulin 10 units/l. The perfusate was gassed with 5% C02-95% 02 to maintain a pH of 7.3-7.4. The heart was stimulated at 75 beats/min using a bipolar platinum electrode embedded in a corner of the septum. Hypoxia was created by equilibrating perfusate (with or without glucose) with 5% C02-95% N2. Total global ischemia was created by turning off the perfusion pump. Preparations were allowed to equilibrate in oxygenated perfusate for at least 1 Metabolic assays. To measure tissue metabolites, the septum was smash-frozen with aluminum tongs precooled in liquid nitrogen and quickly immersed in liquid nitrogen. Tissue samples were later pulverized and digested with 3 M perchloric acid, after which tissue creatine phosphate, creatine, ATP, ADP, and AMP were determined using a high-performance liquid chromatography as described previously.20 To measure lactate production, samples of venous effluent were collected for 15-30 seconds and immediately placed in ice. Lactate content was later determined by standard spectrophotometric techniques.20
Isolated Ventricular Myocyte Experiments
Myocyte isolation. Guinea pigs (200-300 g) of either sex were anesthetized with an overdose of intraperitoneally administered pentobarbital sodium. The heart was quickly removed through a thoracotomy incision and mounted in a Langendorff perfusion apparatus. Single ventricular myocytes were isolated by enzymatic digestion with collagenase and protease as described by Mitra and Morad.21 Patch-clamp methods. Cells were placed in an experimental chamber (0.5-ml capacity) mounted on a stage of an inverted microscope and were continuously perfused at a rate of 1-4 ml/min. Patch electrodes were fabricated from 8161 glass (Corning Glass Inc., Corning, N.Y.) and, when filled with internal solution, had a tip resistance of 1-2 MQl for the whole-cell clamp experiments and [2] [3] [4] Mfl for the excised patch experiments. Patch electrodes were mounted on the head stage of an EPC-7 (List Biological Laboratories, Inc., Campbell, Calif.) or an Axopatch 1B (Axon Instruments, Burlingame, Calif.) patch-clamp amplifier controlled either manually with an external pulse generator or by computer using PCLAMP software (Axon Instruments). Membrane current and voltage signals were recorded on a chart recorder and videocassette recorder or computer hard disk for later analysis. Capacitance compensation and the series resistance compensation were used in the whole-cell clamp experiments. All patch-clamp experiments were performed at room temperature (22-24°C).
Whole-cell voltage-clamp experiments. The patch electrode solution contained (mM) KCl+KOH 145, HEPES 10, EGTA 14, CaCl2 2, NaCI 5, and MgCl2 1, pH 7.2. In most experiments, the solution also contained (mM) K+ADP 1, KH2PO4 1, NAD 1, and Na+ pyruvate 2 as substrates for oxidative metabolism. The bath perfusate was a modified Tyrode's solution containing (mM) NaCI 136, NaOH 9, NaH2PO4 0.33, KCl 5.4, CaCI2 1.8, MgCI2 1, HEPES 10, and glucose 10, pH 7.35. To inhibit oxidative and glycolytic metabolism, 0.1-1 ,uM carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone and 10 mM 2-deoxyglucose were added to glucose-free bath perfusate. In most experiments, the myocyte was held at a membrane potential of -60 mV and voltage-clamped repetitively at 0.2 Hz to -90 mV for 50-100 msec. After exposure to the metabolic inhibitors, the holding current became progressively outward as IKA was activated. After it reached a steady-state level, glibenclamide or tolbutamide was added to the bath. Since IKATP once activated, sometimes ran down fairly quickly, changes in membrane current were attributed to the drugs only if they produced a clear and rapid change in the current level, which reversed at least partially after drug washout.
Excised membrane-patch experiments. The patch electrode solution contained (mM) KCl mM KCl in both the patch electrode and bath solution, the patch electrode was held at +40 or -40 mV to examine inward or outward currents through KATP channels, respectively. KATP channels in the patch were activated by switching the rapid perfusion device to ATP-free bath solution. Patches generally contained >10 KATP channels, and the effects of ATP, ADP, or glibenclamide on channel activity were immediate, so that recording membrane current for 10-12 seconds was fully adequate to assess the effects of a given intervention while minimizing rundown of the channels. Each intervention was bracketed by exposure to control ATP-free, drug-free solution. Data were accepted for analysis only if the current in ATP-free, drug-free solution after the intervention returned to >80% of the control preintervention current in this solution. One exception to the criteria was in the experiments using glibenclamide concentrations of .100 ,uM, which usually irreversibly suppressed current through KATP channels.
Drugs and Chemicals
All chemicals were obtained from Sigma Chemical and 0.31±0.37 (p<0.001) gmol/g by 10 and 100 ,uM glibenclamide, respectively ( Figure 3 ). In comparison, during hypoxia with 5.6 mM glucose present, unidirectional K' efflux rate increased by 43±2% after 10 minutes of hypoxia plus solvent and by 14±8% after 10 minutes of hypoxia plus 100 ,LM glibenclamide ( Figure 2 ). The total K' efflux attributable to the increase in K' efflux rate over the full 10-minute period of hypoxia was reduced from 5.86±0.81 to 2.40±1.26 ,umol/g (p<0.05) by 100 ,tM glibenclamide ( Figure 3 ). Thus, 100 ,uM glibenclamide was less effective at blocking the increase in K' efflux during hypoxia with glucose present than during substrate-free hypoxia. Figure 4 summarizes the changes in APD, developed tension, resting tension, and venous lactate content during aerobic perfusion and hypoxia in the presence and absence of glibenclamide. Under aerobic conditions, glibenclamide had no significant effects on APD (compare 0-and 20-minute data points), but both 10 and 100 ,uM glibenclamide greatly attenuated APD shortening during substratefree hypoxia (30- TIME (minutes)
A-- hypoxia with glucose present than during substratefree hypoxia, and glibenclamide attenuated the increase in lactate production in both conditions. Figure 6 summarizes the results using the same protocol in groups of hearts exposed to 10 or 100 ,M glibenclamide or to 1 Glibenclamide (100 ,uM) also attenuated APD shortening during ischemia from a 25+3% decrease to a 10±4% decrease after 10 minutes of ischemia (p=0.085, Figure 6 ). Neither glibenclamide nor tolbutamide significantly affected the decline in developed tension during ischemia, and rest tension did not increase significantly during ischemia.
Effects of Sulfonylureas on IKAr During Complete Metabolic Inhibition in Isolated Ventricular Myocytes
The limited ability of high concentrations of sulfonylureas at preventing cellular K' loss during myocardial ischemia and hypoxia in the intact ventricle could be explained by two possibilities: either activation of KATP channels is not the major cause of cellular K' loss under these conditions or the ability of sulfonylureas to block KATP channels is impaired during ischemia and hypoxia. To address these possibilities, we examined the effects of sulfonylureas in isolated guinea pig ventricular myocytes under whole-cell patch-clamp conditions in which IKAIP was unequivocally activated by exposure to metabolic inhibitors. Figure 7 illustrates representative examples in three myocytes. The myocytes were held at -60 mV and repetitively voltageclamped (at 0.2 Hz) to -90 mV for 100 msec. At the arrows, the myocytes were exposed to glucose-free bath solution containing carbonyl cyanide p-(trifiuoromethoxy)phenylhydrazone and 2-deoxyglucose to inhibit mitochondrial and glycolytic metabolism. In most experiments, this solution also contained ethanol in an equivalent amount used to solubilize glibenclamide. The holding current at -60 mV became progressively outward, and the current during the clamps to -90 mV became progressively inward as IKAT was activated. After IKATP reached a stable level, the myocytes were exposed to glibenclamide. In a minority of myocytes (six separated by 30- Figure 8A and for 10 mM tolbutamide in Figure 8B . ever, glibenclamide was markedly less effective at blocking KAT channels ( Figure 11 ). In the absence of glibenclamide or ATP, 100 ,uM ADP stimulated current through KATP channels by 19+3%, consistent with previous observations.25 With 100 ,M ADP present, the peak blocking effect of glibenclamide was modest (26±6%) and occurred at a concentration of 1 ,uM, with lower or higher concentrations having less effect ( Figure 10 , filled circles). Paradoxically, very high glibenclamide concentrations (100 and 300 ,uM) had no effect at blocking KAT channels in the presence of 100 ,uM ADP ( Figure 11 , right tracing). After removal of these high concentrations of glibenclamide, current through KAT channels would decrease markedly but could sometimes be restored toward the control level by exposure to 100 ,uM ADP alone (e.g., Figure 11 , right upper tracing).
To test the concentration range over which ADP interfered with the ability of glibenclamide to block KATP channels, [ADP] was varied from 3 to 1,000 ,uM in the presence of a fixed glibenclamide concentration of 1 ,uM. The response of several individual inside-out patches is illustrated in Figure 12 , and the average data from all the patches studied are shown in Figure 13 . ADP myocytes.32 In isolated myocytes, however, the complex environment of the ischemic or hypoxic intact heart cannot be completely simulated. Therefore, a specific and effective blocker of KATP channels is necessary to quantitatively assess the contribution of KATP channels to cellular K+ loss and electrophysiological changes during hypoxia and ischemia in intact tissue. As selective blockers of KATP channels, the sulfonylureas would seem to be excellent candidates. However, the potency of sulfonylureas at blocking KATP channels has been typically characterized in excised membrane patches in the absence of ADP. In the intact cell, free cytosolic [ADP] , calculated by assuming that the creatine kinase reaction is at equilibrium, has been estimated to be in the 30 ,uM range2333 and rapidly increases during hypoxia and ischemia to the 100 ,uM range.3334 When the same method is used (Table 1) , the free cytosolic [ADP] in the rabbit septum was estimated at 15 ,uM under control conditions, rising to 60-100 ,LM after 10 minutes of hypoxia. As our results indicate, ADP in this concentration range markedly interferes with the ability of glibenclamide and tolbutamide to block KATP channels. We believe that this action of ADP significantly compromises the usefulness of even extremely high concentrations of these drugs for quantitatively evaluating the contribution of KATP channels to cellular K' loss and APD shortening during myocardial hypoxia and ischemia. Paradoxically, ADP has been reported to facilitate the tolbutamide block of KATP channels in pancreatic fl-islet cells. 35 This difference could be related to the higher ADP concentration (1 mM) used in that study or else to an organ-specific difference, since pancreatic KATP channels also are generally more sensitive to inhibition by sulfonylureas than are cardiac KATP channels.36,37
Effects of Sulfonylureas on IK in Metabolically Inhibited Isolated Myocytes
The ability of ADP to prevent block of KATP channels by glibenclamide and tolbutamide in excised membrane patches is consistent with the results of the whole-cell voltage-clamp experiments in which IKAT was activated by complete metabolic inhibition. Since 1 mM ADP was included in the patch electrode in most experiments to allow the myocytes to generate ATP endoge- A A_ more prominent, lactate production was less, and glibenclamide was almost completely effective at preventing cellular K' loss. The nearly complete effectiveness of 100 ,uM glibenclamide at blocking the increase in unidirectional K' efflux was greater than would be predicted from the dose-response curve of KATP channels to glibenclamide with ADP, present in excised inside-out patches (Figure 10 ). This may be related to experimental differences, such as the use of different species and temperature, or to the possibility that undefined cytosolic factors not simulated in isolated myocytes modulate the ADPglibenclamide interaction in the intact heart. The fact that glibenclamide was applied to the intracellular membrane surface in the isolated patch experiments but extracellularly in the intact heart experiments is probably not important, since sulfonylureas have been previously reported to block KATP channels with similar effectiveness by either route. 35, 3740 Finally, we cannot exclude the possibility that activation of other types of K' channels, such as Na4-activated8 or arachidonic acid-activated K' channels,7 also makes a significant contribution to total cellular K' loss during hypoxia or with the ability of sulfonylureas to block the channel by competing for the same binding site, seems inconsistent with the complex effect of the ADP-sulfonylurea interaction illustrated in Figures 11 and 12 . Figure 16 shows the essential features of a twobinding site model. argued that blocking the activation of IKATP during ischemia would, by preserving the action potential in the ischemic zone, prolong the time window before the arrhythmogenic ischemic zone became inexcitable, possibly facilitating arrhythmias under some conditions. Furthermore, the preservation of excitability and, hence, contractility in the ischemic zone would reduce the cardioplegic effect conferred by activation of IKATP-Sulfonylureas also prevent hypoxic vasodilation in coronary vascular smooth muscle48,49 and, in the intact animal, produce hypoglycemia. For these reasons, extensive additional experimental studies in clinically relevant models will be necessary to weigh the potential advantages and disadvantages of KATP channel blockade during myocardial ischemia. The findings of this study suggest that the currently available sulfonylureas are not completely effective at blocking IKATP during myocardial ischemia and require such high doses to achieve partial blockade that extracardiac actions of these drugs (e.g., hypoglycemia) will seriously limit their potential for clinical usefulness. However, as newer, more selective KATP channel antagonists are developed, these limitations may be overcome.
Appendix
The K' efflux through KATP channels can be expressed as IKAI=gK&A(Em-EK), where gKAT. is the macroscopic conductance of the channels and Em and EK are the membrane potential and K' equilibrium potential, respectively. Since IKAT shows little voltage dependence over the range of membrane potentials relevant to the action potential,6'50, g is essentially constant and lKAT, is therefore directly proportional to the timeaveraged driving force (Em-EK). By attenuating APD shortening during ischemia, glibenclamide will increase the time-averaged driving force for K' efflux through KATP channels, since the driving force is much greater during systole than diastole. This effect will tend to offset the reduction in [K+]0 accumulation resulting from the glibenclamide-induced decrease in gKATP. However, it can be shown from the data in Figure 4 that this effect is likely to be modest. By assuming an average driving force of 15 mV during diastole and 90 mV during systole after 10 minutes of ischemia, at a constant pacing cycle length of 800 msec the time-averaged driving force for K' efflux would be 30 mV for an APD of 160 msec (in the absence of glibenclamide) and 34 mV for an APD of 200 msec (in the presence of 100 ,uM glibenclamide). Thus, if glibenclamide had not prevented APD shortening during ischemia, [K'], accumulation may have been maximally reduced by glibenclamide by an additional 13%. A similar argument applies to cellular K' loss during substrate-free hypoxia, in which APD shortening was also attenuated by glibenclamide.
